Quantum Capital Management LLC NJ Cuts Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Quantum Capital Management LLC NJ lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 26.5% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 56,208 shares of the company’s stock after selling 20,238 shares during the quarter. IDEXX Laboratories comprises approximately 4.0% of Quantum Capital Management LLC NJ’s holdings, making the stock its 13th biggest holding. Quantum Capital Management LLC NJ’s holdings in IDEXX Laboratories were worth $31,583,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in IDXX. Signature Equity Partners LLC raised its position in shares of IDEXX Laboratories by 412.8% in the 1st quarter. Signature Equity Partners LLC now owns 241 shares of the company’s stock worth $135,000 after buying an additional 194 shares during the period. Alesco Advisors LLC An ESL Co purchased a new stake in IDEXX Laboratories during the first quarter valued at about $292,000. ABN Amro Investment Solutions increased its stake in IDEXX Laboratories by 7.6% during the first quarter. ABN Amro Investment Solutions now owns 3,790 shares of the company’s stock worth $2,130,000 after acquiring an additional 268 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in IDEXX Laboratories by 5.4% during the first quarter. PNC Financial Services Group Inc. now owns 45,739 shares of the company’s stock worth $25,700,000 after acquiring an additional 2,355 shares during the last quarter. Finally, Johnson Financial Group Inc. increased its stake in IDEXX Laboratories by 2,994.4% during the first quarter. Johnson Financial Group Inc. now owns 1,671 shares of the company’s stock worth $939,000 after acquiring an additional 1,617 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

IDXX has been the topic of several research analyst reports. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. Citigroup began coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target on the stock. Finally, UBS Group decreased their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Six analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Trading Down 1.4%

Shares of IDXX opened at $545.00 on Thursday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. IDEXX Laboratories, Inc. has a one year low of $518.55 and a one year high of $769.98. The stock has a 50-day moving average price of $555.83 and a 200 day moving average price of $596.69. The company has a market capitalization of $42.99 billion, a P/E ratio of 40.13, a P/E/G ratio of 3.02 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period in the prior year, the company posted $2.91 EPS. IDEXX Laboratories’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.